Ed Mathers has more than 30 years of experience in the biotechnology and pharmaceutical industries spanning investing, corporate and business development, and sales and marketing. He joined NEA in 2008 as a Partner focused on biotechnology and specialty pharmaceutical investments. Prior to joining NEA, Ed served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. He was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. He was previously Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems and spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline) in sales and marketing positions roles.
In addition to ObsEva, he is a director of Liquidia Technologies, Ra Pharmaceuticals, Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic, Mirna Therapeutics, Lumos Pharma and Ziarco. He is also a member of NC State’s College of Sciences Foundation board. Previously he was a board member of Lumena (sold to Shire), Plexxikon (sold to Daiichi Sankyo), Intarcia, Satori Pharmaceuticals, Southeast Bio, MedImmune, LLC, and the Biotechnology Industry Organization (BIO). He earned his bachelor’s degree in chemistry from North Carolina State University.